Making stem cell transplants a little easier

Hematopoietic stem cell transplants have huge potential in treating cancers, rare genetic disorders, and even autoimmune diseases like multiple sclerosis. But in order to receive a new infusion of stem cells — such as bone marrow — patients have to undergo an extremely toxic conditioning regimen. Typically, that means intense chemotherapy. 

Conditioning winds up being the limiting factor in which patients can undergo these stem cell transplants. A new startup called Jasper Therapeutics is developing new conditioning agents that might even be safe in extremely ill or weak patients. 

The Stanford spinout just launched with a $35 million Series A round.